FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550344014> ?p ?o ?g. }

• W2550344014 endingPage "420" @default.
• W2550344014 startingPage "415" @default.
• W2550344014 abstract "Introduction Pulmonary carcinoids (PCs) are classed according to the World Health Organization 2004 classification as typical or atypical carcinoids. Owing to their rarity, no dedicated clinical trials with somatostatin analogs (SSAs) have been carried out on primary PCs. Patients and Methods From January 2007 to December 2015, 30 patients with metastatic PCs underwent first-line SSA treatment (20 with octreotide long-acting repeatable 30 mg and 10 with lanreotide 120 mg every 28 days). Eight (23.3%) patients had typical carcinoids and 23 (76.7%) had atypical carcinoids. Results The median age was 65.5 years (range, 47-82 years). All patients (23 males and 7 females) were Gallium-68-DOTA-TOC-positron emission tomography/computed tomography (PET/CT)-positive (29 patients) or octreoscan-positive (1 patient). Of the 20 patients who performed fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT), 14 (70.0%) were positive and 6 negative (30.0%). The median treatment duration was 10 months (range, 2-59 months). One patient achieved a partial response (3.3%), and 26 (86.6%) showed stable disease. One patient interrupted SSA treatment owing to symptomatic cholelithiasis. Five-year survival was 53.0% (95% confidence interval [CI], 15.0%-80.0%). The median progression-free survival (mPFS) was 11.1 months (95% CI, 7.0-15.0 months). Negative 18FDG-PET/CT patients had an mPFS of 15.2 months (95% CI, 7.6 months to not reached) compared with 7.0 months (95% CI, 4.0-10.1 months) for 18FDG-PET/CT-positive patients. No differences in mPFS were found in relation to TTF1-value, histologic subtype, and presence of extrahepatic metastases. Conclusion SSAs showed antitumor activity in terms of disease control rate and PFS and proved safe, even in patients with poor Eastern Cooperative Oncology Group status. 18FDG-PET/CT would appear to be a prognostic factor." @default.
• W2550344014 created "2016-11-30" @default.
• W2550344014 creator A5015241599 @default.
• W2550344014 creator A5016057883 @default.
• W2550344014 creator A5016193335 @default.
• W2550344014 creator A5026993525 @default.
• W2550344014 creator A5037063652 @default.
• W2550344014 creator A5044657023 @default.
• W2550344014 creator A5046802560 @default.
• W2550344014 creator A5050243008 @default.
• W2550344014 creator A5075055655 @default.
• W2550344014 creator A5080003827 @default.
• W2550344014 date "2017-07-01" @default.
• W2550344014 modified "2023-10-17" @default.
• W2550344014 title "Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18 FDG-PET/CT" @default.
• W2550344014 cites W1990509102 @default.
• W2550344014 cites W1997325115 @default.
• W2550344014 cites W2077123995 @default.
• W2550344014 cites W2095640694 @default.
• W2550344014 cites W2099704328 @default.
• W2550344014 cites W2125291171 @default.
• W2550344014 cites W2125448413 @default.
• W2550344014 cites W2135049144 @default.
• W2550344014 cites W2137142564 @default.
• W2550344014 cites W2137309473 @default.
• W2550344014 cites W2149214723 @default.
• W2550344014 cites W2178853365 @default.
• W2550344014 cites W2209368665 @default.
• W2550344014 cites W2278865006 @default.
• W2550344014 doi "https://doi.org/10.1016/j.cllc.2016.11.004" @default.
• W2550344014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27956089" @default.
• W2550344014 hasPublicationYear "2017" @default.
• W2550344014 type Work @default.
• W2550344014 sameAs 2550344014 @default.
• W2550344014 citedByCount "25" @default.
• W2550344014 countsByYear W25503440142017 @default.
• W2550344014 countsByYear W25503440142018 @default.
• W2550344014 countsByYear W25503440142019 @default.
• W2550344014 countsByYear W25503440142020 @default.
• W2550344014 countsByYear W25503440142021 @default.
• W2550344014 countsByYear W25503440142022 @default.
• W2550344014 countsByYear W25503440142023 @default.
• W2550344014 crossrefType "journal-article" @default.
• W2550344014 hasAuthorship W2550344014A5015241599 @default.
• W2550344014 hasAuthorship W2550344014A5016057883 @default.
• W2550344014 hasAuthorship W2550344014A5016193335 @default.
• W2550344014 hasAuthorship W2550344014A5026993525 @default.
• W2550344014 hasAuthorship W2550344014A5037063652 @default.
• W2550344014 hasAuthorship W2550344014A5044657023 @default.
• W2550344014 hasAuthorship W2550344014A5046802560 @default.
• W2550344014 hasAuthorship W2550344014A5050243008 @default.
• W2550344014 hasAuthorship W2550344014A5075055655 @default.
• W2550344014 hasAuthorship W2550344014A5080003827 @default.
• W2550344014 hasConcept C126322002 @default.
• W2550344014 hasConcept C126838900 @default.
• W2550344014 hasConcept C2775842073 @default.
• W2550344014 hasConcept C2776256026 @default.
• W2550344014 hasConcept C2776297358 @default.
• W2550344014 hasConcept C2777433750 @default.
• W2550344014 hasConcept C2779066768 @default.
• W2550344014 hasConcept C2779609023 @default.
• W2550344014 hasConcept C2781025020 @default.
• W2550344014 hasConcept C2984496839 @default.
• W2550344014 hasConcept C2989005 @default.
• W2550344014 hasConcept C44249647 @default.
• W2550344014 hasConcept C71315377 @default.
• W2550344014 hasConcept C71924100 @default.
• W2550344014 hasConcept C90924648 @default.
• W2550344014 hasConceptScore W2550344014C126322002 @default.
• W2550344014 hasConceptScore W2550344014C126838900 @default.
• W2550344014 hasConceptScore W2550344014C2775842073 @default.
• W2550344014 hasConceptScore W2550344014C2776256026 @default.
• W2550344014 hasConceptScore W2550344014C2776297358 @default.
• W2550344014 hasConceptScore W2550344014C2777433750 @default.
• W2550344014 hasConceptScore W2550344014C2779066768 @default.
• W2550344014 hasConceptScore W2550344014C2779609023 @default.
• W2550344014 hasConceptScore W2550344014C2781025020 @default.
• W2550344014 hasConceptScore W2550344014C2984496839 @default.
• W2550344014 hasConceptScore W2550344014C2989005 @default.
• W2550344014 hasConceptScore W2550344014C44249647 @default.
• W2550344014 hasConceptScore W2550344014C71315377 @default.
• W2550344014 hasConceptScore W2550344014C71924100 @default.
• W2550344014 hasConceptScore W2550344014C90924648 @default.
• W2550344014 hasIssue "4" @default.
• W2550344014 hasLocation W25503440141 @default.
• W2550344014 hasLocation W25503440142 @default.
• W2550344014 hasOpenAccess W2550344014 @default.
• W2550344014 hasPrimaryLocation W25503440141 @default.
• W2550344014 hasRelatedWork W1987719339 @default.
• W2550344014 hasRelatedWork W1992285201 @default.
• W2550344014 hasRelatedWork W2093457022 @default.
• W2550344014 hasRelatedWork W2126451936 @default.
• W2550344014 hasRelatedWork W2226335814 @default.
• W2550344014 hasRelatedWork W2619085378 @default.
• W2550344014 hasRelatedWork W2963723926 @default.
• W2550344014 hasRelatedWork W4224280629 @default.
• W2550344014 hasRelatedWork W4225380096 @default.
• W2550344014 hasRelatedWork W4289130323 @default.

• next